Phase 2 Trial Recruiting Early-stage Huntington’s Patients to Test Neflamapimod for Improving Cognition

Phase 2 Trial Recruiting Early-stage Huntington’s Patients to Test Neflamapimod for Improving Cognition

Publication date: Jul 23, 2019

This post was originally published on this site EIP Pharma is launching a proof-of-concept Phase 2 clinical trial to assess the ability of therapeutic candidate neflamapimod to treat cognitive dysfunction in patients with early-stage Huntington’s disease. -We believe that neflamapimod has the potential to treat cognitive impairments associated with Huntington’s disease and can therefore benefit patients early in the course of their disease,” John Alam, MD, founder and CEO of EIP Pharma, said in a press release. Neflamapimod is also being tested in a Phase 2 trial (NCT02423122) in Alzheimer’s disease and has led to significant improvements in episodic memory function in patients with early disease. The post Phase 2 Trial Recruiting Early-stage Huntington’s Patients to Test Neflamapimod for Improving Cognition appeared first on Huntington’s Disease News. The post Phase 2 Trial Recruiting Early-stage Huntington’s Patients to Test Neflamapimod for Improving Cognition appeared first on BioNewsFeeds.

Concepts Keywords
Alzheimer Hippocampus
Brain Memory
Cambridge Aphasias
CEO Psychiatric diagnosis
Clinical Trial Cognitive disorders
Cognitive Neuropsychology
Cognitive Dysfunction Neuroscience
Cross Cognitive science
Enzyme Due excessive inflammation
Episodic Memory Limbic system
Executive Function Episodic memory
Hippocampus Alzheimer’s disease
Huntington Delirium
Inflammation Alpha
Maze
Memory
Nerve
P38
Pipeline
Placebo
Reaction Time
Small Molecule
Spatial Learning
Synapse
Synapses
Synaptic
Test
Toxicity
Virtual Water
Working Memory

Semantics

Type Source Name
gene UNIPROT SMIM10L2A
gene UNIPROT SMIM10L2B
disease MESH CNS diseases
disease MESH development
pathway BSID Release
disease MESH visual
drug DRUGBANK Water
gene UNIPROT ARMC9
gene UNIPROT AKR1A1
gene UNIPROT WASHC1
disease MESH inflammation
gene UNIPROT CRK
gene UNIPROT MAPK1
gene UNIPROT AHSA1
gene UNIPROT GRAP2
gene UNIPROT POLDIP2
gene UNIPROT MAPK14
gene UNIPROT AIMP2
gene UNIPROT TNIP1
disease MESH cognitive dysfunction
gene UNIPROT SLC35G1
drug DRUGBANK Neflamapimod

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *